|
Application value of low-dose computed tomography combined with serum tumor markers in diagnosis of early non-small cell lung cancer
|
R. Xu   , W. Xu , D. Liu , S. Pan , J. Zhu , Y. Shen , C. Wang , H. Shen |
| Department of Thoracic Surgery, Shandong Public Health Clinical Center (Shandong Provincial Chest Hospital), Shandong Province, China , qie85615604@163.com |
|
|
Abstract: (418 Views) |
Background: We aimed to explore the application value of low-dose computed tomography (LDCT) combined with serum tumor markers in the diagnosis of early non-small cell lung cancer (NSCLC). Materials and Methods: The clinical data of 176 patients suspected of early NSCLC screened from March 2017 to April 2022 were retrospectively collected. The diagnostic values of LDCT, serum tumor markers, and LDCT combined with serum tumor markers for early NSCLC were explored. Results: There were diverse imaging characteristics of early NSCLC, dominated by solid lesions, followed by part-solid nodules, but non-solid nodules were rare. The levels of serum carcinoembryonic antigen, cytokeratin 19 fragment antigen 21-1 and neuron specific enolase in patients with early NSCLC were higher than those in patients with benign lesions (P<0.05). LDCT combined with serum tumor markers had a higher Kappa coefficient than LDCT and serum tumor markers, indicating that it had the highest consistency with pathological diagnosis results (P<0.05). Both the sensitivity and accuracy of LDCT combined with serum tumor markers were higher than those of LDCT and serum tumor markers (P<0.05). Conclusion: LDCT combined with serum tumor markers can significantly improve the diagnostic sensitivity and accuracy for early NSCLC and the consistency with pathological diagnosis results, and effectively reduce misdiagnosis and missed diagnosis. |
|
| Keywords: Computed tomography, early diagnosis, non-small cell lung cancer, serum, tumor markers. |
|
|
Full-Text [PDF 664 kb]
(82 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Sarıhan SÜ, Tunç S, Irem Z, Kahraman AY (2024) Stereotactic radiotherapy for brain metastases in patients with non-small cell lung cancer: CyberKnife-M6 experience. Int J Radiat Res, 22(1): 117-124. [ DOI:10.61186/ijrr.22.1.117] 2. Chen H, Laba JM, Boldt RG, et al. (2018) Stereotactic ablative radiotherapy versus surgery in early lung cancer: a meta-analysis of propensity score studies. Int J Radiat Oncol Biol Phys, 101(1): 186-194. [ DOI:10.1016/j.ijrobp.2018.01.064] 3. Passiglia F, Cinquini M, Bertolaccini L, et al. (2021) Benefits and harms of lung cancer screening by chest computed tomography: a systematic review and meta-analysis. J Clin Oncol, 39(23): 2574-2585. [ DOI:10.1200/JCO.20.02574] 4. Jiang T, Ren S, Zhou C (2020) Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention. Signal Transduct Target Ther, 5(1): 95. [ DOI:10.1038/s41392-020-0210-2] 5. Gholizadeh-Ansari M, Alirezaie J, Babyn P (2020) Deep learning for low-dose CT denoising using perceptual loss and edge detection layer. J Digit Imaging, 33(2): 504-515. [ DOI:10.1007/s10278-019-00274-4] 6. O'Dowd EL and Ten Haaf K (2019) Lung cancer screening: enhancing risk stratification and minimising harms by incorporating information from screening results. Thorax, 74(9): 825-827. [ DOI:10.1136/thoraxjnl-2019-213156] 7. Grover H, Ross T, Fuller E (2020) Implementation of targeted screening for lung cancer in a high-risk population within routine NHS practice using low-dose computed tomography. Thorax, 75(4): 348-350. [ DOI:10.1136/thoraxjnl-2019-214303] 8. Kalinke L, Thakrar R, Janes SM (2021) The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers. Mol Oncol, 15(10): 2544-2564. [ DOI:10.1002/1878-0261.12864] 9. Reich JM (2006) Estimated impact of LDCT-identified stage IA non-small-cell lung cancer on screening efficacy. Lung Cancer, 52(3): 265-271. [ DOI:10.1016/j.lungcan.2006.02.007] 10. Sivunen J, Piirilä P, Karlberg S, et al. (2020) Restriction of lung volumes but normal function of pulmonary tissue in mulibrey nanism. Pediatr Pulmonol, 55(1): 122-129. [ DOI:10.1002/ppul.24518] 11. Tokito T, Azuma K, Yamada K, et al. (2019) Prognostic value of serum tumor markers in patients with stage iii nsclc treated with chemoradiotherapy. In Vivo, 33(3): 889-895. [ DOI:10.21873/invivo.11555] 12. Dal Bello MG, Filiberti RA, Alama A, et al. (2019) The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med, 17: 74. [ DOI:10.1186/s12967-019-1828-0] 13. Qu T, Zhang J, Xu N, et al. (2019) Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer. Oncol Lett, 17(5): 4293-4298. [ DOI:10.3892/ol.2019.10073] 14. Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T (2018) Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report. Oncol Lett, 16(4): 4219-4222. [ DOI:10.3892/ol.2018.9158] 15. Yuan J, Sun Y, Wang K, et al. (2022) Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction. BMC Cancer, 22(1): 686. [ DOI:10.1186/s12885-022-09728-5] 16. Lv X, Cao J, Dai X, Rusidanmu A (2018) Survival rates after lobectomy versus sublobar resection for early-stage right middle lobe non-small cell lung cancer. Thorac Cancer, 9(8): 1026-1031. [ DOI:10.1111/1759-7714.12782] 17. Zhang Z, Yuan F, Chen R, et al. (2020) Dynamics of serum tumor markers can serve as a prognostic biomarker for Chinese advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. Front Immunol, 11: 1173. [ DOI:10.3389/fimmu.2020.01173] 18. Chu GCW, Lazare K, Sullivan F (2018) Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC Cancer, 18(1): 181. [ DOI:10.1186/s12885-018-4024-3] 19. Jiang R, Dong X, Zhu W, et al. (2017) Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers. PLoS One, 12(9): e0184338. [ DOI:10.1371/journal.pone.0184338] 20. Rao S, Smith DA, Guler E, et al. (2021) Past, present, and future of serum tumor markers in management of ovarian cancer: a guide for the radiologist. Radiographics, 41(6): 1839-1856. [ DOI:10.1148/rg.2021210005] 21. Padinharayil H, Varghese J, John MC, et al. (2023) Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis, 10(3): 960-989. [ DOI:10.1016/j.gendis.2022.07.023] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Xu R, Xu W, Liu D, Pan S, Zhu J, Shen Y, et al . Application value of low-dose computed tomography combined with serum tumor markers in diagnosis of early non-small cell lung cancer. Int J Radiat Res 2025; 23 (1) :77-81 URL: http://ijrr.com/article-1-5948-en.html
|
